晚期HCC-话题@MedSci

#晚期HCC#

10篇内容 | 1212人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1704001, encodeId=4d3c1e0400171, content=<a href='/topic/show?id=286a59e974d' target=_blank style='color:#2F92EE;'>#晚期HCC#</a>, objectTitle=Nature：临床数据表明，仑伐替尼联合吉非替尼是晚期HCC的潜在疗法, objectType=article, longId=214858, objectId=0b4121485899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b4121485899, replyNumber=0, likeNumber=82, createdTime=2022-01-10, rootId=0, userName=caobinglei8089, userId=0aab30610862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b4121485899, moduleTitle=Nature：临床数据表明，仑伐替尼联合吉非替尼是晚期HCC的潜在疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b4121485899)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704003, encodeId=1a481e04003ea, content=<a href='/topic/show?id=286a59e974d' target=_blank style='color:#2F92EE;'>#晚期HCC#</a>, objectTitle=Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比, objectType=article, longId=221201, objectId=587522120103, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=587522120103, replyNumber=0, likeNumber=68, createdTime=2022-07-03, rootId=0, userName=caobinglei8089, userId=0aab30610862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=587522120103, moduleTitle=Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=587522120103)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704002, encodeId=8a791e0400231, content=<a href='/topic/show?id=286a59e974d' target=_blank style='color:#2F92EE;'>#晚期HCC#</a>, objectTitle=Liver Cancer：阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期！, objectType=article, longId=216224, objectId=35e921622426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35e921622426, replyNumber=0, likeNumber=84, createdTime=2022-02-04, rootId=0, userName=caobinglei8089, userId=0aab30610862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35e921622426, moduleTitle=Liver Cancer：阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35e921622426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704000, encodeId=3e5f1e0400050, content=<a href='/topic/show?id=286a59e974d' target=_blank style='color:#2F92EE;'>#晚期HCC#</a>, objectTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, objectType=article, longId=211491, objectId=32e221149157, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32e221149157, replyNumber=0, likeNumber=84, createdTime=2021-07-20, rootId=0, userName=caobinglei8089, userId=0aab30610862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32e221149157, moduleTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32e221149157)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703999, encodeId=dda41e039997e, content=<a href='/topic/show?id=286a59e974d' target=_blank style='color:#2F92EE;'>#晚期HCC#</a>, objectTitle=JAMA Oncol：传统治疗方式的“逆袭” :TACE+放疗治疗晚期HCC患者, objectType=article, longId=134331, objectId=97871343311c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97871343311c, replyNumber=0, likeNumber=69, createdTime=2019-03-18, rootId=0, userName=caobinglei8089, userId=0aab30610862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97871343311c, moduleTitle=JAMA Oncol：传统治疗方式的“逆袭” :TACE+放疗治疗晚期HCC患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97871343311c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703998, encodeId=a7801e039982b, content=<a href='/topic/show?id=286a59e974d' target=_blank style='color:#2F92EE;'>#晚期HCC#</a>, objectTitle=JCO：局部晚期HCC患者是否推荐放射性栓塞治疗, objectType=article, longId=132144, objectId=b8ed13214436, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ed13214436, replyNumber=0, likeNumber=71, createdTime=2018-04-06, rootId=0, userName=caobinglei8089, userId=0aab30610862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ed13214436, moduleTitle=JCO：局部晚期HCC患者是否推荐放射性栓塞治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ed13214436)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703997, encodeId=52b41e03997ed, content=<a href='/topic/show?id=286a59e974d' target=_blank style='color:#2F92EE;'>#晚期HCC#</a>, objectTitle=AASLD特约点评 | 赵明教授：Checkmate-040 研究——Nivolumab治疗晚期HCC的数据更新, objectType=article, longId=121557, objectId=f7f212155e0e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7f212155e0e, replyNumber=0, likeNumber=103, createdTime=2018-04-09, rootId=0, userName=caobinglei8089, userId=0aab30610862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7f212155e0e, moduleTitle=AASLD特约点评 | 赵明教授：Checkmate-040 研究——Nivolumab治疗晚期HCC的数据更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f7f212155e0e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703996, encodeId=3b9f1e03996fd, content=<a href='/topic/show?id=286a59e974d' target=_blank style='color:#2F92EE;'>#晚期HCC#</a>, objectTitle=Lancet 重磅！瑞格菲尼在治疗晚期HCC的3期临床试验获得成功, objectType=article, longId=87963, objectId=6f318e96342, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f318e96342, replyNumber=0, likeNumber=111, createdTime=2017-01-27, rootId=0, userName=caobinglei8089, userId=0aab30610862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f318e96342, moduleTitle=Lancet 重磅！瑞格菲尼在治疗晚期HCC的3期临床试验获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f318e96342)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703995, encodeId=a1a41e0399566, content=<a href='/topic/show?id=286a59e974d' target=_blank style='color:#2F92EE;'>#晚期HCC#</a>, objectTitle=EASL 2014：LY2157299治疗晚期HCC的安全性剂量评估, objectType=article, longId=33350, objectId=08053335022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08053335022, replyNumber=0, likeNumber=78, createdTime=2014-06-28, rootId=0, userName=caobinglei8089, userId=0aab30610862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08053335022, moduleTitle=EASL 2014：LY2157299治疗晚期HCC的安全性剂量评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08053335022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703994, encodeId=6d2b1e03994a2, content=<a href='/topic/show?id=286a59e974d' target=_blank style='color:#2F92EE;'>#晚期HCC#</a>, objectTitle=索拉菲尼治疗晚期HCC控制率达到半数, objectType=article, longId=7485, objectId=61a0e4856c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61a0e4856c, replyNumber=0, likeNumber=75, createdTime=2012-08-07, rootId=0, userName=caobinglei8089, userId=0aab30610862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61a0e4856c, moduleTitle=索拉菲尼治疗晚期HCC控制率达到半数, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61a0e4856c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期HCC

2020-05-29

caobinglei8089 (审核中...)

前往app查看评论内容

#晚期HCC#

Nature：临床数据表明，仑伐替尼联合吉非替尼是晚期HCC的潜在疗法

2022-01-10

caobinglei8089 (审核中...)

前往app查看评论内容

#晚期HCC#

Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比

2022-07-03

caobinglei8089 (审核中...)

前往app查看评论内容

#晚期HCC#

Liver Cancer：阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期！

2022-02-04

caobinglei8089 (审核中...)

前往app查看评论内容

#晚期HCC#

Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性

2021-07-20

caobinglei8089 (审核中...)

前往app查看评论内容

#晚期HCC#

JAMA Oncol：传统治疗方式的“逆袭” :TACE+放疗治疗晚期HCC患者

2019-03-18

caobinglei8089 (审核中...)

前往app查看评论内容

#晚期HCC#

JCO：局部晚期HCC患者是否推荐放射性栓塞治疗

2018-04-06

caobinglei8089 (审核中...)

前往app查看评论内容

#晚期HCC#

AASLD特约点评 | 赵明教授：Checkmate-040 研究——Nivolumab治疗晚期HCC的数据更新

2018-04-09

caobinglei8089 (审核中...)

前往app查看评论内容

#晚期HCC#

Lancet 重磅！瑞格菲尼在治疗晚期HCC的3期临床试验获得成功

2017-01-27

caobinglei8089 (审核中...)

前往app查看评论内容

#晚期HCC#

EASL 2014：LY2157299治疗晚期HCC的安全性剂量评估

2014-06-28

caobinglei8089 (审核中...)

前往app查看评论内容

#晚期HCC#

索拉菲尼治疗晚期HCC控制率达到半数

2012-08-07

科室
- - 订阅+
  - 更多科室
工具
服务